G B Fox

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety
    Ana M Basso
    Neuroscience, Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Eur J Pharmacol 540:115-20. 2006
  2. ncbi Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
    Gerard B Fox
    CNS Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 131:151-61. 2002
  3. ncbi Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 re
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 313:176-90. 2005
  4. ncbi Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Inflamm Res 53:S49-50. 2004
  5. ncbi Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Rd, Abbott Park, Illinois 60064-6115, USA
    Inflamm Res 52:S31-2. 2003
  6. ncbi Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia
    G B Fox
    Neuroscience Research, Abbott Laboratories, AP9A, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064, USA
    Inflamm Res 54:S23-4. 2005
  7. ncbi Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 305:897-908. 2003
  8. ncbi Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 72:741-50. 2002
  9. ncbi A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series
    M Cowart
    Abbott Laboratories, GPRD Neuroscience Research, R4MN, AP9A-216, Abbott Park, IL 60064-6123, USA
    Inflamm Res 56:S47-8. 2007
  10. ncbi H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization
    Victoria A Komater
    Neuroscience Research, Abbott Laboratories, AP9A, D4N5, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 167:363-72. 2003

Collaborators

Detail Information

Publications59

  1. ncbi Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety
    Ana M Basso
    Neuroscience, Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Eur J Pharmacol 540:115-20. 2006
    ..The lack of efficacy with four structurally different MCH-1 receptor antagonists does not support a role for therapeutic treatment of depression/anxiety via this mechanism of action...
  2. ncbi Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
    Gerard B Fox
    CNS Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 131:151-61. 2002
    ..c.) blocked the pro-cognitive effects of ciproxifan, suggesting an H(3) receptor site of action for this compound. This model is useful for evaluating the cognition/attention-enhancing potential of H(3) receptor antagonists...
  3. ncbi Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 re
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 313:176-90. 2005
    ..0 mg/kg), but not striatum. In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia...
  4. ncbi Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Inflamm Res 53:S49-50. 2004
  5. ncbi Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Rd, Abbott Park, Illinois 60064-6115, USA
    Inflamm Res 52:S31-2. 2003
  6. ncbi Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia
    G B Fox
    Neuroscience Research, Abbott Laboratories, AP9A, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064, USA
    Inflamm Res 54:S23-4. 2005
  7. ncbi Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 305:897-908. 2003
    ..A-304121 and A-317920 represent a series of novel, H3R-selective piperazine amides that enhance cognition in vivo, which could offer advantages over existing H3R antagonists or cognition-enhancing agents...
  8. ncbi Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 72:741-50. 2002
    ..This new dipsogenia model provides the first in vivo behavioral evidence for possible pharmacological differences between three putative H(3) receptor inverse agonists, GT-2331 and proxyfan...
  9. ncbi A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series
    M Cowart
    Abbott Laboratories, GPRD Neuroscience Research, R4MN, AP9A-216, Abbott Park, IL 60064-6123, USA
    Inflamm Res 56:S47-8. 2007
  10. ncbi H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization
    Victoria A Komater
    Neuroscience Research, Abbott Laboratories, AP9A, D4N5, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 167:363-72. 2003
    ..CONCLUSIONS: H(3) receptor blockade may offer a safer alternative to psychomotor stimulants for the treatment of ADHD...
  11. ncbi Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists
    M Cowart
    Department R4MN, AP9A-216, Abbott Laboratories, Global Pharmaceutical Research and Development, 100 Abbott Park Road, Abbott Park, IL 60064-6123, USA
    Inflamm Res 54:S25-6. 2005
  12. ncbi Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties
    R Faghih
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6123, USA
    Inflamm Res 53:S79-80. 2004
  13. ncbi Minimization of potential hERG liability in histamine H3 receptor antagonists
    L A Black
    Abbott Laboratories, GPRD Neuroscience Research, R4MN, AP9A-216, 100 Abbott Park Road, Abbott Park, IL 60064-6123, USA
    Inflamm Res 57:S45-6. 2008
  14. ncbi Effects of histamine H3 receptor antagonists in two models of spatial learning
    Victoria A Komater
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 159:295-300. 2005
    ..Taken together, these data suggest a role for H3 receptors in spatial learning that appears to be task-dependent...
  15. ncbi Pharmacological MRI in awake rats predicts selective binding of alpha4beta2 nicotinic receptors
    Chih Liang Chin
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Synapse 62:159-68. 2008
    ..Our data demonstrate the utility of using phMRI in awake animals to characterize selective pharmacological action but also highlight an important confound (anesthesia) that is rarely considered in preclinical phMRI studies...
  16. ncbi D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor
    R Faghih
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP-9A, R4MN, Abbott Park, IL 60064-6123, USA
    Inflamm Res 52:S47-8. 2003
  17. ncbi The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
    Michael E Ballard
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 190:1-11. 2007
    ..Neuroleptic dysphoria encompasses a range of unpleasant subjective responses and, as a result, is difficult to study in preclinical animal models...
  18. ncbi The medicinal chemistry of novel H(3) antagonists
    M Cowart
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6123, USA
    Inflamm Res 53:S69-70. 2004
  19. ncbi Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist
    O El-Kouhen
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    Br J Pharmacol 149:761-74. 2006
    ..The lack of separation between efficacy and side effects in pre-clinical models indicates that mGluR1 antagonism may not provide an adequate therapeutic window for the development of such antagonists as novel analgesic agents in humans...
  20. ncbi Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI
    C L Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Br J Pharmacol 153:367-79. 2008
    ..To address selectivity in vivo, we describe non-invasive, non-ionizing, functional data that distinguish CB1 from CB2 receptor neural activity using pharmacological MRI (phMRI) in awake rats...
  21. ncbi Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice
    F Luo
    Experimental Imaging Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, R46R, AP9 1, Abbott Park, IL 60064, USA
    Neuroscience 155:263-9. 2008
    ..Further, this technique can be readily applied to preclinical screening in a longitudinal manner for novel drugs or antibodies targeting disease modification...
  22. ncbi Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice
    Feng Luo
    Translational Imaging and Biochemical Biomarkers, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Pharmacol Exp Ther 335:580-8. 2010
    ..A highly selective antibody for soluble Aβ is needed to address the question of whether antibodies that do not bind to deposited Aβ have microhemorrhage liability...
  23. ncbi Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment
    Peter Curzon
    Neuroscience Research, Abbott Laboratories GPRD, Abbott Park, IL 60064 6115, United States
    Neurosci Lett 410:15-9. 2006
    ....
  24. ncbi ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects
    Eric G Mohler
    Neuroscience Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 95:146-57. 2010
    ..Moreover, a reduction in omissions was more reliably observed than improvements in accuracy, resulting in a net increase in signals successfully detected...
  25. ncbi ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature
    Yanping Luo
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Anticancer Drugs 20:483-92. 2009
    ..Microtubule disruption and morphological changes in vascular endothelial cells may be responsible, at least in part, for the dysfunction of tumor blood vessels after ABT-751 treatment...
  26. ncbi Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Neuroimmunol 211:49-55. 2009
    ..Collectively, our results provide new insights into the pathophysiology of this animal model of MS...
  27. ncbi Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity
    Marlon Cowart
    GPRD_AP9a 216, Department of Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064 6123, USA
    Biochem Pharmacol 73:1243-55. 2007
    ..v. administration (t(1/2) in rat of 2.9h, 1.7h in dog, 1.8h in monkey), suggesting poor human pharmacokinetics, the data overall indicated that A-688057 has an excellent profile for use as a pharmacological tool compound...
  28. ncbi Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment
    Feng Luo
    Experimental Imaging, Abbott Laboratories, Abbott Park, USA
    J Psychiatr Res 43:1018-24. 2009
    ..The initial transient state and later steady state CBF and CBV responses to a hypercapnic challenge were measured...
  29. ncbi Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge
    Feng Luo
    Experimental Imaging Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Magn Reson Imaging 26:557-63. 2007
    ..To compare and contrast the pattern and characteristics of the cerebral blood volume (CBV) response to ethanol (EtOH) in rats under awake and anesthetized conditions...
  30. ncbi Cloning and characterization of the monkey histamine H3 receptor isoforms
    Marina I Strakhova
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, R 4MN, AP9A, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    Eur J Pharmacol 601:8-15. 2008
    ....
  31. ncbi Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists
    Robert J Altenbach
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 50:5439-48. 2007
    ..Further studies on the pharmaceutic properties of this series of quinolines discovered a potential problem with photochemical instability, an issue which contributed to the discontinuation of this series from further development...
  32. ncbi Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and
    Betty B Yao
    Neurological Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R47W, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 328:141-51. 2009
    ..These data demonstrate that A-836339 is a useful tool for use of studying CB(2) receptor pharmacology and for investigation of the role of CB(2) receptor modulation for treatment of pain in preclinical animal models...
  33. ncbi Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121
    Jia Bao Pan
    Neuroscience Research, Abbott Laboratories, 100 Abbott Road, Abbott Park, IL 60064 6125, USA
    Life Sci 79:1366-79. 2006
    ..The implications for potential long-term treatment with H(3) receptor antagonists in CNS disorders such as ADHD are discussed...
  34. ncbi Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders
    Timothy A Esbenshade
    Division of Neuroscience Research, Global Pharmaceutical Research and Development, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Mol Interv 6:77-88, 59. 2006
    ..Herein, we describe the biological and chemical implications for developing H3 receptor antagonists and their therapeutic potential as disclosed through animal models of cognition, sleep, and obesity...
  35. ncbi Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist
    Timothy A Esbenshade
    Abbott Laboratories, Global Pharmaceutical Research Division, Department of Neuroscience Research, Abbott Park, IL 60064, USA
    Biochem Pharmacol 68:933-45. 2004
    ..Thus, A-349821 is a novel, selective non-imidazole H3 antagonist/inverse agonist with balanced high potency across species and favorable cognition enhancing effects in rats...
  36. ncbi Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan
    Kaitlin E Browman
    Neuroscience Research, Abbott Laboratories, AP9A, 100 Abbott Park, Abbott Park, IL 60064 6115, USA
    Behav Brain Res 153:69-76. 2004
    ..Further, these data suggest that H3 receptor antagonists/inverse agonists have anti-psychotic potential for disorders such as schizophrenia...
  37. ncbi D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist
    Michael P Curtis
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Arch Pharm (Weinheim) 337:219-29. 2004
    ..This compound was shown to demonstrate in vitro and in vivo functional antagonism and is non-neurotoxic at doses (i.p.) up to 163 mg/kg in a general observation test...
  38. ncbi Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists
    Ramin Faghih
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park 60064 6123, USA
    Bioorg Med Chem Lett 13:1325-8. 2003
    ..Most compounds were highly potent and selective for human and rat H(3) receptors and selected examples such as A-349821 showed functional antagonism of H(3) receptors in vitro and in a mouse dipsogenia model...
  39. ncbi Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist
    Arthur A Hancock
    Abbott Laboratories, Global Pharmaceutical Research and Development, 100 Abbott Park Road, Abbott Park, IL 60064 6125, USA
    Eur J Pharmacol 487:183-97. 2004
    ..The two higher doses reduced body fat and the highest dose also normalized an insulin tolerance test. These data show that the histamine H(3) receptor antagonist, A-331440, has potential as an antiobesity agent...
  40. ncbi Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists
    Gregory A Gfesser
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 14:673-6. 2004
    ..Compound 14bb is a potent antagonist of both the rat cortical and human clone receptors, and is demonstrated to act functionally as an antagonist in an in vivo mouse dipsogenia model...
  41. ncbi Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects
    Timothy A Esbenshade
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, R4MN, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 305:887-96. 2003
    ..7 and 7.0) than are the imidazole antagonists. These novel and selective piperazine amides represent useful leads for the development of H3R antagonist therapeutic agents...
  42. ncbi Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs
    Ramin Faghih
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6123, USA
    Bioorg Med Chem Lett 12:2035-7. 2002
    ..Structure-activity relationship studies on novel non-imidazole, D-amino acid containing ligands of histamine 3 receptors are presented. A-304121 is a D-alanine piperazine amide with high affinity at the rat H(3) receptor...
  43. ncbi Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1
    Ramin Faghih
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6123, USA
    Bioorg Med Chem Lett 12:2031-4. 2002
    ..A high throughput screening lead, A-923, was further elaborated in a systematic manner to clarify a pharmacophore for this class of aryloxyalkyl piperazine based compounds...
  44. ncbi Perspectives on cognitive domains, H3 receptor ligands and neurological disease
    Arthur A Hancock
    Abbott Laboratories, Department R4MN, Building AP9A 3, Neuroscience Division, 100 Abbott Park Road, Abbott Park, IL 60064 6125, USA
    Expert Opin Investig Drugs 13:1237-48. 2004
    ..However, because of the complexities of the histaminergic system and H(3) receptors and the lack of clinical data so far, proof of principle for use in human disease remains to be established...
  45. ncbi Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties
    Timothy A Esbenshade
    Neuroscience Research, Abbott Laboratories, R4MN, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 313:165-75. 2005
    ..Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties...
  46. ncbi Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6115, USA
    Neuropsychopharmacology 31:1382-92. 2006
    ..In summary, the present study indicates that PPI-enhancing effects induced by antipsychotics in DBA/2J mice and in NVH-lesioned rats are unlikely to be mediated by D(3) receptors...
  47. ncbi A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats
    Kaitlin E Browman
    Neuroscience Research, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 82:148-55. 2005
    ..CP226269 showed a significant enhancement in the 5-trial inhibitory avoidance model. These results support a role for the dopamine D4 receptor subtype in cognition...
  48. ncbi Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity
    William J Giardina
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6125, USA
    Epilepsia 46:1349-61. 2005
    ..ABT-769 has a broad-spectrum profile like that of valproic acid. Its profile is clearly different from those of carbamazepine, phenytoin, lamotrigine, topiramate, vigabatrin, and tiagabine...
  49. ncbi Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park, Abbott Park, IL 60064 6115, USA
    Brain Res 1045:142-9. 2005
    ....
  50. ncbi 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention
    Marlon Cowart
    Department of Neuroscience Research, Abbott Laboratories, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 48:38-55. 2005
    ..The potency and selectivity of this compound and of analogues from this class support the potential of H(3) receptor antagonists for the treatment of cognitive dysfunction...
  51. ncbi Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test
    Ana M Basso
    Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Neuropsychopharmacology 30:1257-68. 2005
    ..The pharmacological selectivity of the compounds tested suggests that the antidepressant-like effects of quinpirole are most likely mediated mainly by D(2) and to a lesser extent by D(3) but not D(4) receptors...
  52. ncbi Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography
    M Day
    Translational Imaging and Biochemical Biomarkers Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Neuroscience 189:299-304. 2011
    ..Further studies that would establish the translation from mice to non-human primates to humans need to be investigated to confirm the utility of FDG-PET in dose-selection for mitochondrial modulators...
  53. ncbi Translational neuroimaging of the CNS: novel pathways to drug development
    Gerard B Fox
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064
    Mol Interv 9:302-13. 2009
    ..In this brief review, we highlight examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research...
  54. ncbi Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis
    Chih-Liang Chin
    Global Pharmaceutical Research and Development, Abbott Laboratories, R46R Bldg. AP9-1, 100 Abbott Park Road, Abbott Park, IL 60064-6119, USA
    Neuroimage 33:1152-60. 2006
    ..Our data thus suggest that phMRI in awake rats may be a useful tool for predicting emetic liability of CNS-acting drugs and may provide insights into depicting the underlying emetic neural pathways in vivo...
  55. ncbi Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties
    Karin R Tietje
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    CNS Neurosci Ther 14:65-82. 2008
    ....
  56. ncbi Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats
    P D Skoubis
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R4CL, AP9-1, 100 Abbott Park Road, Abbott Park, IL 60064-6118, USA
    Neuroscience 137:583-91. 2006
    ....
  57. ncbi Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice
    Alan I Faden
    Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Room EP 12, Washington, DC 20057, USA
    J Cereb Blood Flow Metab 23:355-63. 2003
    ..In addition, they show that 35b has a relatively wide therapeutic window and improves cognitive function after both acute and chronic injury...
  58. ncbi Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test
    Mark Day
    Discovery Translational Medicine, Wyeth Research, 500 Arcola Road, PA 19426, USA
    Biochem Pharmacol 73:1123-34. 2007
    ..We also expanded on previous positive findings by others with ciproxifan on attention and both Wyeth and Abbott demonstrate for the first time decreased impulsivity with this mechanism...
  59. ncbi Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic
    Mark Day
    PsychoGenics Inc, Cognitive Neurosciences, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Curr Opin Investig Drugs 9:696-706. 2008
    ....